BioPharmSignal logoBioPharmSignal

Biotech News

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Acrivon Therapeutics (ACRV)Acrivon TherapeuticsCompany update

Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical

Related news

ACRVAcrivon Therapeutics2026-08-12 20:05 EST

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

ACRVAcrivon Therapeutics2026-09-02 12:00 EST

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

LEGNLegend Biotech Corporation2026-09-15 12:00 EST

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

KURAKura Oncology2026-09-08 11:00 EST

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

FATEFate Therapeutics2026-10-02 11:00 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATEFate Therapeutics2026-10-01 11:00 EST

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

CGEMCullinan Therapeutics, Inc.2026-09-21 16:00 EST

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

ELVNEnliven Therapeutics2026-09-03 20:05 EST

Enliven Therapeutics to Present at Upcoming Investor Conferences

View all latest news

Acrivon Therapeutics

Generative Phosphoproteomics Platform Acrivon Therapeutics uses its AP3 platform to measure drug-regulated signaling inside intact cells and identify tumors most likely to respond to specific medicines. ACR-368 ACR-368 is a CHK1/2 inhibitor in a registrational-intent Phase 2b study, with increasing focus on serous endometrial cancer and...

Recent company news

ACRVAcrivon Therapeutics2026-09-02 12:00 EST

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

ACRVAcrivon Therapeutics2026-09-02 12:00 EST

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

ACRVAcrivon Therapeutics2026-08-31 12:30 EST

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

ACRVAcrivon Therapeutics2026-08-31 12:30 EST

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

ACRVAcrivon Therapeutics2026-08-12 20:05 EST

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Stock data

Close
1.99 USD
Market cap
67.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States